COX-2 inhibitors: balancing the hope, the hype, and the concern.
Mandell
B F
BF
D002318:Cardiovascular Diseases / Q000401:mortality*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D015201:Meta-Analysis as Topic; D011451:Prostaglandin-Endoperoxide Synthases; D012306:Risk
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases